ROIV

Roivant Sciences Ltd

ROIV, USA

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

https://roivant.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ROIV
stock
ROIV

Insider Selling: Roivant Sciences (NASDAQ:ROIV) Major Shareholder Sells $16,752,432.88 in Stock MarketBeat

Read more →
ROIV
stock
ROIV

Roivant Sciences (NASDAQ:ROIV) Major Shareholder Sells $7,800,077.25 in Stock MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$24.5455

Analyst Picks

Strong Buy

6

Buy

3

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

3.45

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-2.60 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-2.24 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-12,317.76 %

Low 5%

High 15%

Debt to Equity

-

Very High

0.06

Low 1

High 0.3

Investors

* Institutions hold a combined 81.16% of the total shares of Roivant Sciences Ltd

1.

SB INVESTMENT ADVISERS (UK) LTD

(8.7794%)

since

2025/06/30

2.

FMR Inc

(8.1287%)

since

2025/06/30

3.

Morgan Stanley - Brokerage Accounts

(6.5449%)

since

2025/06/30

4.

BlackRock Inc

(5.9038%)

since

2025/06/30

5.

Vanguard Group Inc

(5.7589%)

since

2025/06/30

6.

Viking Global Investors LP

(5.0137%)

since

2025/06/30

7.

Qvt Financial LP

(4.3026%)

since

2025/06/30

8.

Fidelity Growth Compy Commingled Pl S

(3.8307%)

since

2025/07/31

9.

Rubric Capital Management LP

(2.983%)

since

2025/06/30

10.

State Street Corp

(2.8956%)

since

2025/06/30

11.

Fidelity Growth Company Fund

(2.8086%)

since

2025/07/31

12.

iShares Core S&P Mid-Cap ETF

(2.0067%)

since

2025/08/31

13.

Vanguard Total Stock Mkt Idx Inv

(1.9213%)

since

2025/07/31

14.

Patient Square Capital

(1.8275%)

since

2025/06/30

15.

Two Seas Capital LP

(1.552%)

since

2025/06/30

16.

Vanguard Small Cap Index

(1.4499%)

since

2025/07/31

17.

Dimensional Fund Advisors, Inc.

(1.1548%)

since

2025/06/30

18.

Geode Capital Management, LLC

(1.135%)

since

2025/06/30

19.

SPDR® S&P Biotech ETF

(1.056%)

since

2025/08/31

20.

Fidelity Growth Company K6

(0.8314%)

since

2025/07/31

21.

Vanguard Small Cap Growth Index Inv

(0.8159%)

since

2025/07/31

22.

UBS Group AG

(0.7458%)

since

2025/06/30

23.

Fidelity Series Growth Company

(0.7383%)

since

2025/07/31

24.

Anchorage Advisors, LLC

(0.7077%)

since

2025/06/30

25.

BlackBarn Capital Partners LP

(0.6773%)

since

2025/06/30

26.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6615%)

since

2025/07/31

27.

Bank of New York Mellon Corp

(0.6599%)

since

2025/06/30

28.

MS INVF US Growth I

(0.5909%)

since

2025/06/30

29.

Woodline Partners LP

(0.5858%)

since

2025/06/30

30.

Whitefort Capital Management, LP.

(0.5685%)

since

2025/06/30

31.

MS INVF US Advantage I

(0.5527%)

since

2025/06/30

32.

Baker Bros Advisors LP

(0.5517%)

since

2025/06/30

33.

Morgan Stanley Growth SMA

(0.5249%)

since

2025/06/30

34.

Morgan Stanley Inst Growth I

(0.5249%)

since

2025/06/30

35.

Morgan Stanley Growth

(0.5249%)

since

2025/06/30

36.

SPDR® S&P MIDCAP 400 ETF Trust

(0.4722%)

since

2025/07/31

37.

iShares Biotechnology ETF

(0.3648%)

since

2025/08/31

38.

iShares S&P Mid-Cap 400 Growth ETF

(0.3506%)

since

2025/08/31

39.

Fidelity Extended Market Index

(0.3334%)

since

2025/07/31

40.

DFA US Small Cap I

(0.3225%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.3244

Latest Release

Date

2025-09-30

EPS Actual

-0.17

EPS Estimate

-0.32

EPS Difference

0.15

Surprise Percent

46.875%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Strong Momentum(6.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.